Adrian Rossall

Adrian Rossall has extensive experience in platform engineering and drug design, currently serving as Cofounder and Chief Technology Officer at Dalton since July 2024. Previously, Rossall worked at Exscientia as VP Platform Engineering and Executive Director of Platform Engineering, where responsibilities included building innovative drug design platforms. At AstraZeneca, notable achievements included leading the award-winning Augmented Drug Design platform and managing the Genomics IT Platform delivery. Earlier roles included positions at BIOVIA, ABB, Cellzome, Nestle, and GlaxoSmithKline. Rossall holds an MSc in Chemoinformatics from The University of Sheffield and a BSc in Chemistry from the University of Birmingham.